Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05426252 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 19, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Study site revisedv4
  2. Re-verified, no change to tracked fieldsv3
  3. Primary endpoints revised (3)
    • Secondary endpoint revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate a novel transplant strategy for the long-term benefit of patients with transfusion dependent high-risk thalassemia.
Trial Details
NCT Number NCT05426252
Lead Sponsor The Hospital for Sick Children
Collaborators: Thalassemia Foundation of Canada
Conditions
(from sponsor)		 Thalassemia in Children
Related terms Thalassemia
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov